Clinical Trial

SARC038: Phase 2 Study of Regorafenib and Nivolumab in Osteosarcoma

Active, Not Recruiting Phase 2
View on ClinicalTrials.gov →
Record status
This record was last updated October 31, 2025 (before its estimated November 2025 completion). Its status may not reflect the trial's current state.
Summary
A phase 2 study of regorafenib in combination with nivolumab in patients with refractory or recurrent osteosarcoma.
Protocol Amendment History 15 amendments
This ClinicalTrials.gov record has been amended 15 times since 2021-03-16; most recent amendment 2025-10-29.
Status change: Recruiting → Active, Not Recruiting 2023-03-23
Status change: Not Yet Recruiting → Recruiting 2021-06-11
Trial Details
NCT Number NCT04803877
Lead Sponsor Sarcoma Alliance for Research through Collaboration
Conditions Osteosarcoma, Osteosarcoma in Children, Osteosarcoma Recurrent, Osteosarcoma Metastatic
Enrollment 48 participants
Start Date 2021-06-04
Primary Completion 2025-11 (estimated)
Study Completion 2026-06 (estimated)
Updated on ClinicalTrials.gov 2025-10-31